Moderna Therapeutics Receives $40M in Venture Funds
December 07, 2012
Moderna Therapeutics, a company founded within Flagship Venture Labs, is working to develop “an entirely new way of restoring protein function by enabling the body to produce its own healing proteins,” according to its website. To that end, the Cambridge, Mass.-based company has received over $40 million in total venture funding to date, led by Flagship Ventures. Moderna is working toward clinical trials using human subjects, having already conducted proof-of-concept studies in non-human primate preclinical models.